C-Z3YVEpirium Bio
PGE-2 signaling, oral small molecules, tissue homeostasis
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-Z3YV
C-Z3YVC-Z3YVPGE-2 signaling, oral small molecules, tissue homeostasis
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Epirium Bio PGE-2 signaling, oral small molecules, tissue homeostasis
Epirium Bio is a biopharmaceutical company developing orally bioavailable small molecules that leverage PGE-2 signaling to restore tissue homeostasis, resolve inflammation, stimulate regeneration, and reduce fibrosis. Its lead small molecule, MF-300, is in a Phase 2b study for sarcopenia. The company also cites preclinical efficacy data in spinal muscular atrophy, irritable bowel disease, and idiopathic pulmonary fibrosis, and has conducted a Phase 1 clinical trial of EPM-01 in Becker muscular dystrophy.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Epirium Bio — Translational · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic